We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
Cap. Flow
-$99.6M
Cap. Flow %
-3.9%
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$20M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.2M
3
AMGN icon
Amgen
AMGN
+$14.1M
4
PODD icon
Insulet
PODD
+$13.3M
5
BAX icon
Baxter International
BAX
+$11.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$31.7M
2
CI icon
Cigna
CI
+$22.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$22.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.28%
2 Real Estate 2.09%
3 Miscellaneous 1.37%
4 Industrials 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALT icon
151
Altimmune
ALT
$605M
$265K 0.01%
75,000
– –
FUSN
152
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$203K 0.01%
43,394
– –
CDXS icon
153
Codexis
CDXS
$174M
$194K 0.01%
69,125
– –
HARP
154
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$185K 0.01%
25,991
– –
DTIL icon
155
Precision BioSciences
DTIL
$215M
$118K ﹤0.01%
7,484
– –
SPPI
156
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$110K ﹤0.01%
114,670
– –
ACET icon
157
Adicet Bio
ACET
$84.8M
$98K ﹤0.01%
2,521
– –
PRAX icon
158
Praxis Precision Medicines
PRAX
$9.63B
$86.3K ﹤0.01%
5,000
– –
ORKA
159
Oruka Therapeutics
ORKA
$6.03B
$65.9K ﹤0.01%
2,705
– –
NKTX icon
160
Nkarta
NKTX
$198M
$63.5K ﹤0.01%
28,988
– –
MNK
161
DELISTED
Mallinckrodt plc
MNK
$41.4K ﹤0.01%
35,048
– –
CRBP icon
162
Corbus Pharmaceuticals
CRBP
$211M
$40.3K ﹤0.01%
5,143
– –
YARW
163
Yarrow Bioscience
YARW
$98.8M
$30.5K ﹤0.01%
150
– –
NXGL icon
164
NexGel
NXGL
$3.43M
$10.7K ﹤0.01%
4,243
– –
BLCM
165
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.22K ﹤0.01%
6,000
– –
ADUS icon
166
Addus HomeCare
ADUS
$2.16B
– –
-42,380
Closed -$4.52M
ALGN icon
167
Align Technology
ALGN
$11.2B
– –
-6,925
Closed -$2.31M
AMED
168
DELISTED
Amedisys
AMED
– –
-68,949
Closed -$5.07M
ARWR icon
169
Arrowhead Research
ARWR
$12B
– –
-100,422
Closed -$2.55M
BHVN icon
170
Biohaven
BHVN
$2.33B
– –
-35,087
Closed -$479K
BPMC
171
DELISTED
Blueprint Medicines
BPMC
– –
-67,710
Closed -$3.05M
KURA icon
172
Kura Oncology
KURA
$1.13B
– –
-283,281
Closed -$3.46M
LH icon
173
Labcorp
LH
$27.2B
– –
-46,609
Closed -$9.19M
LNTH icon
174
Lantheus
LNTH
$6.58B
– –
-79,495
Closed -$6.56M
MRSN
175
DELISTED
Mersana Therapeutics
MRSN
– –
-6,495
Closed -$667K
4 5 6
7
8

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Tekla Capital Management held 186 positions worth $2.56B, down 2.7% from $2.63B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $99.6M in Q2 2023, closing 20 positions and reducing 32 holdings. Its most notable exit was Travere Therapeutics, an estimated $9.41M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.

Against the trend, Tekla Capital Management opened a new position in Insulet worth $12.6M.

  • Tekla Capital Management's largest Q2 2023 buy was Insulet: 43,847 shares worth $12.6M.
  • Tekla Capital Management added most to Merck in Q2 2023, an estimated $20M increase.
  • Tekla Capital Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $31.7M.
  • Tekla Capital Management fully exited Travere Therapeutics in Q2 2023, selling an estimated $9.41M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.56B portfolio in Q2 2023.
  • Tekla Capital Management opened 9 new positions and closed 20 in Q2 2023.
  • Tekla Capital Management's portfolio value fell 2.7% quarter-over-quarter to $2.56B.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.